Skip to main content
Top

11-09-2024 | Bronchial Asthma | News

ERS 2024

Ultra-long-acting biologic reduces severe asthma exacerbations

medwireNews: Two doses of depemokimab over a year can significantly reduce the risk for severe asthma exacerbations compared with placebo, show findings from the SWIFT-1/2 phase 3a trials.

Related topics

SPONSORED

Targeting COPD with type 2 inflammation: emerging biologic landscape

  • Live
  • Webinar | 03-12-2024 | 19:00 (CET)

LIVE: Tuesday, 3 December 2024, 19:00-20:30 (CET)

Join us for an insightful session tailored for pulmonologists and healthcare professionals eager to enhance their understanding of COPD and the latest advances in biologic therapies. 

Sponsored by:
  • Sanofi
Developed by: Springer Healthcare
Reserve your place

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases